Tracking binding modes of 1,2,4-trisubstituted imidazolinone P38 MAP kinase and ERK-2 inhibitors

被引:3
|
作者
Rao, Shashidhar N. [1 ]
机构
[1] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA
关键词
p38 MAP Kinase; ERK-2; Docking score; DFG-out; Hydrogen bonding; Spearman-R correlation; pi-Cation interactions; ACTIVATED PROTEIN-KINASE; PANCREATIC-CANCER; DOCKING; IDENTIFICATION; DERIVATIVES; PATHWAYS; DESIGN; SMILES; ERK1/2; CELLS;
D O I
10.1016/j.jmgm.2017.07.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Putative binding modes of recently reported p38 MAP Kinase and ERK-2 inhibitors containing 1,2,4-trisubstituted imidazolinone have been investigated using molecular docking methods In the case of p38 MAP Kinase, X-ray structures with both DFG-in and DFG-out conformations of the activation loop have been employed for docking studies. The present investigations demonstrate that the DFG-out conformation of the activation loop in p38 MAP Kinase accommodates the 1,2,4-tri-substituted imidazolinones with greater computed binding affinities than the alternative DFG-in conformation. The best scoring binding modes in ERK-2 are distinctly different from those found in the p38 MAP Kinase structures. Both sets of binding modes are characterized by an extensive network of hydrophobic and pi-cation interactions, with the hinge region showing little hydrogen bonding propensity with the top-ranked poses. Thus, these docking studies provide a putative pathway for lead optimizations in which hydrogen bonding interactions with the hinge region residues are feasible. (c) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:161 / 171
页数:11
相关论文
共 50 条
  • [1] Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity
    Awadallah, Fadi M.
    Abou-Seri, Sahar M.
    Abdulla, Mohamed M.
    Georgey, Hanan H.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 94 : 397 - 404
  • [2] 1,2,4-Trisubstituted imidazolinones with dual carbonic anhydrase and p38 mitogen-activated protein kinase inhibitory activity
    Georgey, Hanan H.
    Manhi, Fatma M.
    Mahmoud, Walaa R.
    Mohamed, Nehad A.
    Berrino, Emanuela
    Supuran, Claudiu T.
    BIOORGANIC CHEMISTRY, 2019, 82 : 109 - 116
  • [3] Effects of Water Placement on Predictions of Binding Affinities for p38α MAP Kinase Inhibitors
    Luccarelli, James
    Michel, Julien
    Tirado-Rives, Julian
    Jorgensen, William L.
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2010, 6 (12) : 3850 - 3856
  • [4] Synthesis, p38 MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines
    Tariq, Sana
    Alam, Ozair
    Amir, Mohammad
    ARCHIV DER PHARMAZIE, 2018, 351 (3-4)
  • [5] Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold
    Scior, T.
    Domeyer, D. M.
    Cuanalo-Contreras, K.
    Laufer, S. A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (10) : 1526 - 1539
  • [6] Investigation of structure-activity relationship: In silico studies of [1,2,4]triazolo[4, 3-a]pyridine ureas as P38 kinase inhibitors
    Aasiya, Choudhary
    Mangala, Khandekar
    Chandrakant, Bagul
    Muthal, Amol
    Kulkarni, Ravindra
    STRUCTURAL CHEMISTRY, 2023, 34 (03) : 915 - 929
  • [7] Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with p38α MAP Kinase
    Yang, Ying
    Shen, Yulin
    Liu, Huanxiang
    Yao, Xiaojun
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (12) : 3235 - 3246
  • [8] Synthesis and biological activity of 2H-quinolizin-2-one based p38α MAP kinase inhibitors
    Tynebor, Robert M.
    Chen, Meng-Hsin
    Natarajan, Swaminathan R.
    O'Neill, Edward A.
    Thompson, James E.
    Fitzgerald, Catherine E.
    O'Keefe, Stephen J.
    Doherty, James B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2765 - 2769
  • [9] Acute Lymphoid and Gastrointestinal Toxicity Induced by Selective p38α Map Kinase and Map Kinase-Activated Protein Kinase-2 (MK2) Inhibitors in the Dog
    Morris, Dale L.
    O'Neil, Shawn P.
    Devraj, Rajesh V.
    Portanova, Joseph P.
    Gilles, Richard W.
    Gross, Cindy J.
    Curtiss, Sandra W.
    Komocsar, Wendy J.
    Garner, Debra S.
    Happa, Fernando A.
    Kraus, Lori J.
    Nikula, Kristen J.
    Monahan, Joseph B.
    Selness, Shaun R.
    Galluppi, Gerald R.
    Shevlin, Kimberly M.
    Kramer, Jeffrey A.
    Walker, John K.
    Messing, Dean M.
    Anderson, David R.
    Mourey, Robert J.
    Whiteley, Laurence O.
    Daniels, John S.
    Yang, Jerry Z.
    Rowlands, Philip C.
    Alden, Carl L.
    Davis, John W., II
    Sagartz, John E.
    TOXICOLOGIC PATHOLOGY, 2010, 38 (04) : 606 - 618
  • [10] From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors
    Heider, Fabian
    Haun, Urs
    Doering, Eva
    Kudolo, Mark
    Sessler, Catharina
    Albrecht, Wolfgang
    Laufer, Stefan
    Koch, Pierre
    MOLECULES, 2017, 22 (10)